Who is involved
The emergence of the COVID-19 Cicada variant, designated BA.3.2, marks a significant development in the ongoing pandemic. Prior to this, public health expectations were largely centered around the Omicron variant, which had been the dominant strain in many countries, including the UK. Vaccination efforts were robust, with the public largely believing that existing vaccines were effective against circulating variants. However, the arrival of BA.3.2 has shifted this narrative, raising new concerns about the virus’s evolution and its potential impact on public health.
The decisive moment came in late 2024 when the Cicada variant was first detected in South Africa. Since then, it has spread to 23 countries, including the UK, where it has been confirmed as a variant of interest. The variant carries an alarming 70 to 75 genetic changes in its spike protein, which are believed to contribute to its ability to evade antibodies. This has sparked fears that the current COVID-19 vaccines may be less effective against it, as noted by Kyle B. Enfield, who stated, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.”
The immediate effects of the Cicada variant’s emergence have been felt across healthcare systems. Weekly detections of BA.3.2 surged to account for approximately 30% of COVID-19 sequences reported in Denmark, Germany, and the Netherlands between November 2025 and January 2026. This uptick has raised alarms among health officials, as the variant is associated with symptoms such as a particularly painful sore throat, fever, cough, fatigue, and nasal congestion. The CDC has warned that the Cicada strain “could be associated with seasonal increases in COVID-19 activity,” indicating a potential rise in cases as the respiratory virus season approaches.
Experts are closely monitoring the situation, as the variant’s mutations could lead to increased transmissibility. However, it is crucial to note that, as of now, there is no evidence suggesting that the Cicada variant causes more severe disease than previous variants. Kyle B. Enfield reassured the public, stating, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.” This perspective is vital in tempering fears while acknowledging the variant’s potential risks.
Despite the lack of evidence for increased severity, the uncertainty surrounding the variant’s impact on public health remains significant. The exact effects of the Cicada variant are still unclear, particularly due to limited genomic detection and surveillance capacities in many countries. Additionally, the long-term effectiveness of current vaccines against this variant is uncertain, leaving public health officials in a precarious position as they navigate the evolving landscape of the pandemic.
The Cicada variant, named after the insect that lies dormant for years before emerging, reflects the virus’s ability to remain undetected before spreading. Its detection in the UK has prompted health authorities to ramp up surveillance and vaccination efforts, as they prepare for the possibility of increased COVID-19 activity. As the situation develops, it is essential for the public to stay informed and adhere to health guidelines to mitigate the spread of the virus.
In summary, the emergence of the Cicada variant BA.3.2 in the UK represents a critical juncture in the COVID-19 pandemic. With its significant genetic changes and potential implications for vaccine efficacy, the variant underscores the need for continued vigilance and adaptation in public health strategies. Details remain unconfirmed regarding its long-term impact, but the healthcare community remains committed to monitoring and responding to this evolving threat.